Ovid Therapeutics OVID 深 滬
等待開盤 09-08 09:30:00 美东时间
2.80
+0.020
+0.72%
華盛通- 最 高2.825
- 今 開2.74
- 成交量 106.60万股
- 最 低 2.71
- 昨 收 2.78
- 總市值 5.47亿
- 52周最高 3.105
- 市盈率 靜 --
- 換手率 0.55%
- 52周最低 1.12
- 委 比 -94.04%
- 總股本 1.95亿
- 歷史最高 15.89
- 量 比 0.73
- 振 幅 4.14%
- 歷史最低 0.2425
- 每 手 1
- 風險率 0.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ovid Therapeutics Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $733.000K Beat $30.000K Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 27.27 percent. This is a 33.33 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $733.000 tho...
08-13 20:58
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
Oppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9
Oppenheimer analyst Kostas Biliouris maintains Ovid Therapeutics (NASDAQ:OVID) with a Outperform and raises the price target from $7 to $9.
08-03 22:25
Ovid Therapeutics appoints Charles Carter as new CFO
Ovid Therapeutics ( ($OVID) ) has issued an announcement. On July 5, 2026, Ovid...
07-08 19:29
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
Ovid Therapeutics announced several key leadership appointments to strengthen its executive team. Kevin Norrett was appointed Chief Business Officer, Charles Carter promoted to Chief Financial Officer, Eliseo Salinas joined as Executive R&D Advisor, and Victoria Fort became Chief Strategy Officer. These changes aim to support the company's growth and strategic initiatives in developing innovative treatments for brain disorders.
07-08 11:00
uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy
uniQure N.V. (NASDAQ:QURE) on Friday reported initial six-month follow-up data from the first low-dose cohort in its ongoing Phase 1/2a trial evaluating investigational gene therapy candidate AMT-260 in patients with refractory mesial temporal lobe epilepsy (MTLE). MTLE represents the most prevalent...
06-22 23:51
Ovid Therapeutics to Participate in Upcoming Investor Conferences
Ovid Therapeutics announced that its management will participate in two upcoming investor conferences: the Oppenheimer CNS & Neuro-Muscular Summit on June 10 at 3:45 pm ET and the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 15. Presentations will be available via webcast on the company’s website at investors.ovidrx.com, with an archived replay for 30 days post-event.
06-04 11:00
Ovid Therapeutics Expands Board, Appoints New Scientific Director
Ovid Therapeutics ( ($OVID) ) has shared an announcement. On May 29, 2026, Ovid...
06-03 21:51
Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
Ovid Therapeutics Inc. announced the appointment of Dr. Anna Greka as a new Board member, effective June 15, 2026. Dr. Greka, a renowned physician-scientist and entrepreneur, will Chair the Science and Technology Committee and join the Compensation Committee. Her expertise in ion channel biology and therapeutic innovation will support Ovid's development of KCC2 activators and epilepsy programs.
06-03 11:00
Ovid Therapeutics Q1 EPS $(0.12) Misses $(0.11) Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 14.29 percent increase over losses of $(0.14) per share
05-12 19:21
